Fondaparinux

Fondaparinux, sold as Arixtra, is an anticoagulant of the Factor Xa inhibitor type, given by injection under the skin. The US label read lists, in adults, prophylaxis of deep vein thrombosis in people having hip fracture, hip replacement, knee replacement or abdominal surgery, and treatment of acute deep vein thrombosis or acute pulmonary embolism when given with warfarin sodium. It also lists treatment of venous thromboembolism in children aged 1 year or older who weigh at least 10 kg. The label carries a boxed warning about epidural or spinal hematomas in people who are anticoagulated and have neuraxial anesthesia or a spinal puncture.

Also called Arixtra · Fondaparinux sodium

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 321208; UNII X0Q6N9USOZ is the UNII of fondaparinux sodium, the form the label names, and is a broad match. MeSH descriptor D000077425 is Fondaparinux. Class: Factor Xa Inhibitor (FDA established pharmacologic class, RxClass); the label also writes (anticoagulant) after the class name. The label read is the Mylan Institutional LLC label for Arixtra, application NDA021345, effective 2024-12-10 in openFDA. Adult and paediatric statements are kept in separate contexts and claims. This page records label indications, the first sentence of the boxed warning and the class only: no trial result and no dose is given.

About this drug

Level
Substance
Mechanism
The label says fondaparinux, through antithrombin III, selectively inhibits Factor Xa, which interrupts the blood coagulation cascade.

Classification codes

  • UNII X0Q6N9USOZ

Claims and evidence

Context Adults for whom the US label of fondaparinux (Arixtra) lists an indication: prophylaxis of deep vein thrombosis after hip fracture, hip replacement, knee replacement or abdominal surgery; treatment of deep vein thrombosis or acute pulmonary embolism

Recipient
Adult
Population
Adult patients described in the indications sections of the label.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Adults, as the passages read state
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
  • Adult patients undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery or abdominal surgery, for prophylaxis of deep vein thrombosis
  • Adult patients with deep vein thrombosis or acute pulmonary embolism, when administered in conjunction with warfarin sodium
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Arixtra (fondaparinux sodium), in the Mylan Institutional LLC version dated 2024-12-10 in openFDA, describes fondaparinux as a Factor Xa inhibitor (anticoagulant) and lists it, in adult patients, for the prophylaxis of deep vein thrombosis in patients undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery or abdominal surgery, and for the treatment of deep vein thrombosis or acute pulmonary embolism when administered in conjunction with warfarin sodium. The label carries a boxed warning about epidural or spinal hematomas in anticoagulated patients who receive neuraxial anesthesia or undergo spinal puncture.

    Applies to Adult Adults for whom the US label of fondaparinux (Arixtra) lists an indication: prophylaxis of deep vein thrombosis after hip fracture, hip replacement, knee replacement or abdominal surgery; treatment of deep vein thrombosis or acute pulmonary embolism

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for in adults. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The paediatric indication is recorded in a separate claim. Only the indications, the first sentence of the boxed warning and the mechanism sentence were read; contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA also lists generic labels. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (5)
    1. Supports openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective_time). Generic fondaparinux labels in openFDA were not read.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      Label passage quoted in the research quote table (LB-04).
      Retrieved
      Source effective date
      2024-12-10
      Source state
      Current
      Version fingerprint
      1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective_time). Generic fondaparinux labels in openFDA were not read.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE, first bullet
      How it applies
      Label passage quoted in the research quote table (LB-05).
      Retrieved
      Source effective date
      2024-12-10
      Source state
      Current
      Version fingerprint
      1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective_time). Generic fondaparinux labels in openFDA were not read.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE, second bullet
      How it applies
      Label passage quoted in the research quote table (LB-06).
      Retrieved
      Source effective date
      2024-12-10
      Source state
      Current
      Version fingerprint
      1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Supports openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective_time). Generic fondaparinux labels in openFDA were not read.

      Locator
      results[0].boxed_warning[0], sentence 1
      How it applies
      Label passage quoted in the research quote table (LB-08).
      Retrieved
      Source effective date
      2024-12-10
      Source state
      Current
      Version fingerprint
      1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    5. Background openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective_time). Generic fondaparinux labels in openFDA were not read.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20241210.
      Retrieved
      Source effective date
      2024-12-10
      Source state
      Current
      Version fingerprint
      1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Context Children for whom the US label of fondaparinux (Arixtra) lists an indication: venous thromboembolism in pediatric patients aged 1 year or older weighing at least 10 kg

Recipient
Child
Population
Pediatric patients aged 1 year or older who weigh at least 10 kg, as the label states.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Children aged 1 year or older, as the passage read states
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Pediatric patients aged 1 year or older weighing at least 10 kg, with venous thromboembolism
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Arixtra (fondaparinux sodium), in the Mylan Institutional LLC version dated 2024-12-10 in openFDA, lists the medicine for the treatment of venous thromboembolism in pediatric patients aged 1 year or older weighing at least 10 kg.

    Applies to Child Children for whom the US label of fondaparinux (Arixtra) lists an indication: venous thromboembolism in pediatric patients aged 1 year or older weighing at least 10 kg

    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's paediatric use, dosing and safety sections were not read. The adult indications are recorded in a separate claim. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective_time). Generic fondaparinux labels in openFDA were not read.

      Locator
      results[0].indications_and_usage[0], 1.4 Treatment of Venous Thromboembolism in Pediatric Patients
      How it applies
      Label passage quoted in the research quote table (LB-07).
      Retrieved
      Source effective date
      2024-12-10
      Source state
      Current
      Version fingerprint
      1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective_time). Generic fondaparinux labels in openFDA were not read.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20241210.
      Retrieved
      Source effective date
      2024-12-10
      Source state
      Current
      Version fingerprint
      1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Pregnancy, lactation and children

The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.

In newborns, infants and children 1

Claims whose context is a newborn, an infant or a child.

  • Description Evidence stage not applicable Certainty not assessed

    The US label of Arixtra (fondaparinux sodium), in the Mylan Institutional LLC version dated 2024-12-10 in openFDA, lists the medicine for the treatment of venous thromboembolism in pediatric patients aged 1 year or older weighing at least 10 kg.

    Applies to Child Children for whom the US label of fondaparinux (Arixtra) lists an indication: venous thromboembolism in pediatric patients aged 1 year or older weighing at least 10 kg

    Population, setting and follow-up
    • Pediatric patients aged 1 year or older who weigh at least 10 kg, as the label states.
    • Prescription medicine, as described in the US label
    • United States (label of the US Food and Drug Administration)
    • Children aged 1 year or older, as the passage read states
    • Gestational age Not reported
    • Postnatal age Not reported
    Follow-up Not applicable (label statement)
    Certainty method
    Not assessed
    Limitations
    This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's paediatric use, dosing and safety sections were not read. The adult indications are recorded in a separate claim. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-09
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective_time). Generic fondaparinux labels in openFDA were not read.

      Locator
      results[0].indications_and_usage[0], 1.4 Treatment of Venous Thromboembolism in Pediatric Patients
      How it applies
      Label passage quoted in the research quote table (LB-07).
      Retrieved
      Source effective date
      2024-12-10
      Source state
      Current
      Version fingerprint
      1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective_time). Generic fondaparinux labels in openFDA were not read.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20241210.
      Retrieved
      Source effective date
      2024-12-10
      Source state
      Current
      Version fingerprint
      1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.

ARIXTRA

No label from the application holder was found in the openFDA label dataset for application NDA021345. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA021345 ARIXTRA
  2. Supplemental approval NDA021345 ARIXTRA
  3. Supplemental approval NDA021345 ARIXTRA
  4. Supplemental approval NDA021345 ARIXTRA
  5. Supplemental approval NDA021345 ARIXTRA
  6. Supplemental approval NDA021345 ARIXTRA

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 1

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 5 efficacy supplement approvals on record.

    ProductNDA021345

Record details

Record id
cardio:fondaparinux
Content hash
18bb54ee39999d7b46238c5b0a04418e7ee8fd56fc78729e38a295662f0e2d15